1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [ca80e6bf-4538-49ed-8375-26320e81f03f] => Array
        (
            [runtime-id] => ca80e6bf-4538-49ed-8375-26320e81f03f
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [6a6f89b6-f7ba-4e46-9b65-48d3e6a0842e] => Array
                        (
                            [runtime-id] => 6a6f89b6-f7ba-4e46-9b65-48d3e6a0842e
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;034e95935d9e98a1ea29d1681db2ae147000f13f
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [ca80e6bf-4538-49ed-8375-26320e81f03f] => Array
        (
            [runtime-id] => ca80e6bf-4538-49ed-8375-26320e81f03f
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [6a6f89b6-f7ba-4e46-9b65-48d3e6a0842e] => Array
                        (
                            [runtime-id] => 6a6f89b6-f7ba-4e46-9b65-48d3e6a0842e
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;034e95935d9e98a1ea29d1681db2ae147000f13f
                )

        )

)


Table 1: 
Outcomes of intra-arterial therapy in major trials
StudyMean Baseline NIHSSRecanalization (TIMI 2 or 3)Good Outcome at 90 Days (mRS 0–2)Mortality at 90 DaysSymptomatic ICH
Intra-arterial therapy
    PROACT91758%NA27%15%
    PROACT II61766%40%25%10%
    IMS-I81856%43%16%6%
    IMS-II51960%46%16%10%
    MERCI72246%28%44%8%
    Multi MERCI41968%36%34%10%
    Penumbra pivotal study1882%25%33%11%
Nonarterial therapy
    PROACT91914%NA43%7%
    PROACT II2 control1718%25%27%2%
    NINDS placebo*518NA28%24%1%
    NINDS IV rtPA*518NA39%21%7%
  • Note:—NIHSS indicates National Institutes of Health Stroke Scale; TIMI, Thrombolysis in Myocardial Infarction trial; ICH, intracranial hemorrhage; mRS, modified Rankin Scale; PROACT, Prolyse in Acute Cerebral Thromboembolism trial; IMS, Interventional Management of Stroke trials; MERCI, Mechanical Embolus Removal in Cerebral Ischemia trials; NINDS, National Institute of Neurological Disorders and Stroke; NA, not available.
  • * NINDS is subgroup of patients with an NIHSS of 10 or more.